tbuckley/cabot-search huggingface dataset:
Eye-Preserving Therapies for Advanced Retinoblastoma
Authors: Chuandi Zhou, Xuyang Wen, Yi Ding, Jingwen Ding, Mei Jin, Zhenyin Liu, Sha Wang, Minglei Han, Hongfeng Yuan, Yishuang Xiao, Li Wu, Jiancang Wang, Yangjun Li, Jiawei Yu, Yuechun Wen, Juan Ye, Rong Liu, Zhijun Chen, Shangcai Xue, Wei Lu, Hongfei Liao, Jizhe Cui, Dan Zhu, Fang Lu, Song Tang, Yu Wu, Tseden Yangkyi, Guanghong Zhang, Miershalijiang Wubuli, Huiyu Guo, Xian Wang, Yanjin He, Xunlun Sheng, Qing Wang, Yingxiu Luo, Jiayan Fan, Jinlei Qi, Zhangsheng Yu, Jia Tan, Jianhong Liang, Xiantao Sun, Liwen Jin, Xinji Yang, Jing Zhang, Xunda Ji, Junyang Zhao, Renbing Jia, Xianqun Fan
Journal: Ophthalmology (2021)
Refining the Recipe for Alternative Payment Models for Surgical Care—Importance of Patient Mix and Venue Match
Authors: David A. Schwartzman, Kyle H. Sheetz, A. Mark Fendrick
Journal: JAMA Network Open (2021)

Oluseyi Aliu, MD; Andrew W. P. Lee, MD; Jonathan E. Efron, MD; Robert S. D. Higgins, MD; Charles E. Butler, MD; Anaeze C. Offodile II, MD, MPH
Abstract 19602: Characterization of Tgfβ/BMP-axis in Multiple Animal Models of PH
Authors: Chris Happé, Nina Rol, Denielli Da Silva Goncalves Bos, Cathelijne van der Bruggen, Anton Vonk-Noordegraaf, Frances de Man, Harm Jan Bogaard
Journal: Circulation (2015)

Introduction: Mutations in the bone morphogenetic protein recptor type 2 (BMPR2) comprise a large portion of familial Pulmonary Arterial Hypertension (PAH) cases. The transforming growth factor-β (TGF-β)/BMP-axis in PAH has been of interest, which is hypothesized to favor TGF-β signaling due to defective BMPR2 signaling, consequently leading to pro-proliferative signaling within the lung. In addition, it has been proposed that the BMPRII mutations might affect cardiac adaptation. To date none of the available animal models have been fully characterized with regard to the TGF-β/BMP pathway. This study assessed the lung and heart TGF-β/BMP-axis in multiple rat animal models of pulmonary hypertension to ensure translational capability. Methods: Heart and lung TGF-β/BMP-axis was assessed by qPCR, western blot and immunofluorescence in the the monocrotaline (MCT), Sugen-hypoxia (SuHx), Sugen-Pneumonectomy (SuPnx) and Pulmonary artery banding model (PAB) and compared to control and PAH patient tissues. Circulating ligands, TGF-β receptor (TGFβR) type 1 and 2 and BMPR2, and canonical downstream signaling (Smad2/3, Smad1/5/8, and transcription factors) were investigated. Results: BMPR2 was down-regulated at both transcription and protein levels in the lung of all PH animal models (p&lt;0.05). Transcription of pulmonary TGFβR1 and -2 were increased in the SuPNx-model, compared to control (P&lt;0.001). In both SuHx and SuPnx models an increase in protein Smad2/3 expression was observed by immunofluorescence implying overactivation of TGF-β signaling. Cardiac TGFβR1 was decreased in PAB model, compared to control (P&lt;0.05), while TGFβR2 was decreased in both the MCT and PAB model. Conclusion: Early indications reveal differences between several pulmonary hypertension animal models, with regard to the TGF-β/BMP pathway. Additional analysis is needed to fully characterize the regulation of TGF-β and BMP in the rat models.
Evidence of Artemisinin-Resistant Malaria in Africa
Authors: Betty Balikagala, Naoyuki Fukuda, Mie Ikeda, Osbert T. Katuro, Shin-Ichiro Tachibana, Masato Yamauchi, Walter Opio, Sakurako Emoto, Denis A. Anywar, Eisaku Kimura, Nirianne M.Q. Palacpac, Emmanuel I. Odongo-Aginya, Martin Ogwang, Toshihiro Horii, Toshihiro Mita
Journal: New England Journal of Medicine (2021)

In the six Southeast Asian countries that make up the Greater Mekong Subregion, Plasmodium falciparum has developed resistance to derivatives of artemisinin, the main component of first-line treatments for malaria. Clinical resistance to artemisinin monotherapy in other global regions, including Africa, would be problematic.
High Prevalence of Osteopathy in Chronic Pancreatitis: A Cross-sectional Analysis From the PROCEED Study
Authors: Phil A Hart, Dhiraj Yadav, Liang Li, Savi Appana, William Fisher, Evan Fogel, Chris E Forsmark, Walter G Park, Stephen Pandol, Mark D Topazian, Stephen K Van Den Eden, Santhi Swaroop Vege, David Bradley, Jose Serrano, Darwin L Conwell
Journal: Clinical Gastroenterology and Hepatology (2021)
Evolution of Obstructive Lung Function in Advanced Pulmonary Arterial Hypertension
Authors: Farbod N. Rahaghi, Megan Trieu, Faisal Shaikh, Fereidoun Abtin, Alejandro A. Diaz, Lloyd L. Liang, Igor Barjaktarevic, Richard N. Channick, Raúl San José Estépar, George R. Washko, Rajan Saggar
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

"Evolution of Obstructive Lung Function in Advanced Pulmonary Arterial Hypertension." American Journal of Respiratory and Critical Care Medicine, 204(12), pp. 1478–1481
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
Authors: James L. Januzzi, Faiez Zannad, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Stuart J. Pocock, João Pedro Ferreira, Naveed Sattar, Subodh Verma, Ola Vedin, Janet Schnee, Tomoko Iwata, Dan Cotton, Milton Packer
Journal: Journal of the American College of Cardiology (2021)

The relationship between the benefits of empagliflozin in heart failure with reduced ejection fraction (HFrEF) and N-terminal pro–B-type natriuretic peptide (NT-proBNP) has not been reported. The authors sought to evaluate the relationship between NT-proBNP and empagliflozin effects in EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction). Patients with HFrEF were randomly assigned to placebo or empagliflozin 10 mg daily. NT-proBNP was measured at baseline, 4 weeks, 12 weeks, 52 weeks, and 100 weeks. Patients were divided into quartiles of baseline NT-proBNP. Incidence rates for each study outcome were 4- to 6-fold higher among those in the highest versus lowest NT-proBNP quartiles (≥3,480 vs <1,115 pg/mL). Study participants with higher NT-proBNP had 2- to 3-fold total hospitalizations higher than the lowest NT-proBNP quartile. Empagliflozin reduced risk for major cardiorenal events without heterogeneity across NT-proBNP quartiles (primary endpoint Pinteraction = 0.94; renal composite endpoint Pinteraction = 0.71). Empagliflozin treatment significantly reduced NT-proBNP at all timepoints examined; by 52 weeks, the adjusted mean difference from placebo was 13% (P < 0.001). An NT-proBNP in the lowest quartile (<1,115 pg/mL) 12 weeks after randomization was associated with lower risk for subsequent cardiovascular death or heart failure hospitalization regardless of baseline concentration. Treatment with empagliflozin resulted in 27% higher adjusted odds of an NT-proBNP concentration of <1,115 pg/mL by 12 weeks compared with placebo (P = 0.01). In EMPEROR-Reduced, higher baseline NT-proBNP concentrations were associated with greater risk for adverse heart failure or renal outcomes, but empagliflozin reduced risk regardless of baseline NT-proBNP concentration. The NT-proBNP concentration after treatment with empagliflozin better informs subsequent prognosis than pretreatment concentrations. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977)
Challenges to the Development of the Next Generation of Self-Reporting Cardiovascular Implantable Medical Devices
Authors: Antonia Molloy, Kirsten Beaumont, Ali Alyami, Mahmut Kirimi, Daniel Hoare, Nosrat Mirzai, Hadi Heidari, Srinjoy Mitra, Steve L. Neale, John R. Mercer
Journal: IEEE Reviews in Biomedical Engineering (2021)

Cardiovascular disease (CVD) is a group of heart and vasculature conditions which are the leading form of mortality worldwide. Blood vessels can become narrowed, restricting blood flow, and drive the majority of hearts attacks and strokes. Reactive surgical interventions are frequently required; including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Despite successful opening of vessels and restoration of blood flow, often in-stent restenosis (ISR) and graft failure can still occur, resulting in subsequent patient morbidity and mortality. A new generation of cardiovascular implants that have sensors and real-time monitoring capabilities are being developed to combat ISR and graft failure. Self-reporting stent/graft technology could enable precision medicine-based and predictive healthcare by detecting the earliest features of disease, even before symptoms occur. Bringing an implantable medical device with wireless electronic sensing capabilities to market is complex and often obstructive undertaking. This critical review analyses the obstacles that need to be overcome for self-reporting stents/grafts to be developed and provide a precision-medicine based healthcare for cardiovascular patients. Here we assess the latest research and technological advancement in the field, the current devices; including smart cardiovascular implantable biosensors and associated wireless data and power transfer solutions. We include an evaluation of devices that have reached clinical trials and the market potential for their end-user implementation.
Promoting physical activity for mental health in a refugee camp: the Skaramagas project
Authors: Manolis Adamakis
Journal: British Journal of Sports Medicine (2021)

Background 11 Many refugee and migrant children and adolescents are in urgent need of shelter, care, and 12 protection.Greece has been a major entry point in Europe, receiving over a million refugees 13 and migrants (37% children) since the beginning of 2015.These children and their families 14 face a range of risks, such as violence, exploitation, and abuse in their country of origin, during 15 their journey, and upon arrival.It is estimated that 22% of individuals living in displacement 16 experience a mental disorder such as depression, anxiety, posttraumatic stress disorder, bipolar 17 disorder, or schizophrenia. 1 Promising examples of community-based initiatives, which use 18 culturally sensitive learning materials, 2 to encourage participation in physical activity for the 19 purpose of promoting mental health are emerging. 3,4This Service Spotlight focuses on one 20 such initiative: the Skaramagas project.21 22 The Skaramagas project 23 Skaramagas is an old navy base located 11 km west of Athens.During the summer of 2016, 24 Skaramagas accommodated 3,000 refugees, of whom 96% were families from Syria, Iraq, and 25 Afghanistan.
SRCP: a comprehensive pipeline for accurate annotation and quantification of circRNAs
Authors: Avigayel Rabin, Michela Zaffagni, Reut Ashwal-Fluss, Ines Lucia Patop, Aarti Jajoo, Shlomo Shenzis, Liran Carmel, Sebastian Kadener
Journal: Genome biology (2021)

Here we describe a new integrative approach for accurate annotation and quantification of circRNAs named Short Read circRNA Pipeline (SRCP). Our strategy involves two steps: annotation of validated circRNAs followed by a quantification step. We show that SRCP is more sensitive than other individual pipelines and allows for more comprehensive quantification of a larger number of differentially expressed circRNAs. To facilitate the use of SRCP, we generate a comprehensive collection of validated circRNAs in five different organisms, including humans. We then utilize our approach and identify a subset of circRNAs bound to the miRNA-effector protein AGO2 in human brain samples.
COVID-19 in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: case series from the ECZTEND long-term extension trial
Authors: A. Blauvelt, A. Pink, M. Worm, R. Langley, A. Costanzo, L. Gjerum, E. Jorgensen, J. Corriveau, E. Guttman-Yassky
Journal: British Journal of Dermatology (2021)
P07.03 Fluorescence navigation in glioma surgery using 5 ALA and chlorin E6
Authors: A Rynda, V Olyushin, D Rostovtsev
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND Metabolic navigation in the surgery of malignant gliomas is the most effective way to distinguish the border of the tumor during surgery and achieve a more radical resection, and as a result, to increase the recurrence interval and increase the life expectancy. MATERIAL AND METHODS A comparative analysis of fluorescent navigation was carried out in 50 patients (group 2) with glioma of a high degree of anaplasia, who were treated at the Department of Neurooncology of the A.L. prof. A.L. Polenov. In 25 patients (group 1), chlorin E6 1 mg / kg intravenously was used as a fluorescence inducer, the other 25 patients (group 2) received 5 ALA 20 mg / kg orally. Each group included 10 patients with Grade III anaplasia and 15 patients with Grade IV anaplasia. Both groups were statistically representative (p&amp;gt; 0.05). RESULTS For surgery of grade III glioma, the sensitivity of the method was 83.3% (chlorin E6), 82.9% (5ALA); specificity 66.7% (chlorin E6), 65.4% (5ALA). For grade IV glioma surgery, the sensitivity of the method is 87.5% (chlorin E6), 87.7% (5ALA); specificity - 85.7% (chlorin E6), 85.3% (5ALA). CONCLUSION Statistical analysis showed comparable high efficacy of the drugs in the surgery of malignant gliomas. The sensitivity and specificity of the method for fluorescent preparations of chlorin E6 and 5 ALA showed no statistically significant difference in the achievement of the result (p&amp;gt; 0.05)
The Cancer Cell: Dynamic Aspects and Modifications in Cell-Surface Organization
Authors: Garth L. Nicolson, George Poste
Journal: New England Journal of Medicine (1976)

Cell-Surface Modifications on Cancer CellsThe central importance of the cell surface in determining many features of tumor-cell behavior has served to stimulate a massive research effort to identify differences in the surface properties of normal cells and their neoplastic counterparts. This effort has been successful to the extent that an enormous catalogue of differences between normal and tumor-cell populations has been accumulated (Fig. 5).22,23 We now have little insight, however, into the mechanisms by which these manifold changes in surface properties arise in tumor cells and how these changes are maintained. Of more immediate importance . . .
Perceptions of barriers to patient financial hardship screening differ by provider role within gynecologic oncology outpatient care.
Authors: Jhalak Dholakia, Maria Pisu, Warner King Huh, Margaret Irene Liang
Journal: Journal of Clinical Oncology (2021)

317 Background: Although approximately half of patients with gynecologic malignancy experience financial hardship (FH) during treatment, best practices to identify and assist patients with FH are lacking. To develop such practices, we assessed oncology provider and staff perspectives about FH screening and provision of assistance. Methods: An anonymous survey was conducted electronically within the Gynecologic Oncology outpatient office at a Comprehensive Cancer Center. Potential barriers to patient FH screening and follow-up were assessed within 2 domains: 1) logistic barriers to incorporating FH screening and follow-up into outpatient workflow and 2) perceived patient barriers to FH screening. Responses were elicited on a 5-point Likert scale from ‘very’ to ‘not at all’ significant and dichotomized into significant and not significant barriers. Results: Of 43 providers approached, 37 responded (86% response rate) of which 14 were physicians (MD)/nurse practitioners (NP) and 23 were other staff members (i.e., clinical and research nurses, social workers, pharmacists, care coordinators, lay navigators, and financial counselors). Altogether, 38% worked in their current position for &gt;5 years (n=14), 11% for 3-5 years (n=4), and 51% for &lt;3 years (n=19). For logistic barriers to implementing FH screening and follow-up, the most frequently reported significant barriers included lack of personnel training (69%) and lack of available staff (62%), training regarding follow-up (72%), and case tracking infrastructure (67%). The most frequent significant perceived patient barriers were lack of knowledge of whom to contact (72%), concerns about impact on treatment if FH needs were identified (72%), and lack of patient readiness to discuss financial needs (62%.) Compared to MD/NP, staff members more often indicated the following as significant barriers: difficulty incorporating FH screening into initial visit workflow (31 % vs. 57%, p=0.03), overstretched personnel (29% vs 73%, p=0.005), and patient concerns about influence on treatment (62% vs 86%, p=0.01). Conclusions: Care team members identified barriers to patient FH screening across logistic and patient-centered domains, although MD/NP less so than other staff possibly reflecting different exposures to patient financial needs during clinical encounters or burden of workflow. Implementation of universal FH screening, dedicated personnel, convenient tracking mechanisms, and multi-disciplinary provider and staff training may improve recognition of patient FH and facilitate its integration into oncology care plans.
2D materials for bone therapy
Authors: Xiangjiang Wang, Xianjing Han, Chaozhou Li, Zhi Chen, Hao Huang, Jindong Chen, Chenshuo Wu, Taojian Fan, Tianzhong Li, Weichun Huang, Omar A. Al-Hartomy, Ahmed Al-Ghamdi, Swelm Wageh, Fei Zheng, Abdullah G. Al-Sehemi, Guiqing Wang, Zhongjian Xie, Han Zhang
Journal: Advanced Drug Delivery Reviews (2021)
Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers
Authors: Kasper Iversen, Jonas Henrik Kristensen, Rasmus Bo Hasselbalch, Mia Pries-Heje, Pernille Brok Nielsen, Andreas Dehlbæk Knudsen, Kamille Fogh, Jakob Boesgaard Norsk, Ove Andersen, Thea Køhler Fischer, Claus Antonio Juul Jensen, Christian Torp-Pedersen, Jørgen Rungby, Sisse Bolm Ditlev, Ida Hageman, Rasmus Møgelvang, Mikkel Gybel-Brask, Ram B. Dessau, Erik Sørensen, Lene Harritshøj, Fredrik Folke, Curt Sten, Maria Elizabeth Engel Møller, Thomas Benfield, Henrik Ullum, Charlotte Sværke Jørgensen, Christian Erikstrup, Sisse R. Ostrowski, Susanne Dam Nielsen, Henning Bundgaard
Journal: Clinical Microbiology and Infection (2021)
P06.04 Tertiary center experience in the treatment of intracranial germinoma
Authors: I Jabłońska, M Miszczyk, E Nowicka, None Magrowski, R Tarnawski
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND Intracranial germinoma is a rare malignant neoplasm, accounting for approximately two-thirds of central nervous system germ cell tumors, which occurs in the suprasellar region, pineal gland, or basal nuclei in children and young adolescents. Due to the rare occurrence, there is relatively high variability in treatment modalities. This article aims to assess the symptoms, and treatment outcomes of radiotherapy and chemotherapy for intracranial germinoma, based on tertiary center experience. METHODS The study includes retrospectively gathered data from 35 consecutive patients treated for intracranial germinoma between 1999–2020 at a single institution. The statistical analysis used basic statistical tools and the Kaplan-Meier method. RESULTS The median age at diagnosis was 17 years (IQR 14–22), 85.7% of the patients were male. The majority of the patients had histopathological confirmation of the diagnosis (88.5%), 76% of which were non-secreting germinomas. The primary tumor was most frequently localized in the area of the pineal gland (34.3%), followed by bifocal (25.7%), suprasellar (17.1%), and basal germinoma (8.6%). The remaining patients had disseminated disease (14.3%). The most common symptoms at the onset of the disease were headache (54.3%), visual impairment (45.7%), vomiting (25.7%), polydipsia (22.9%), weight loss (17.1%), or minor neurological deficits (11.4%). As much as 54.3% of the patients presented with neuroendocrine disorders at diagnosis, and 42.9% of the patients presented radiological symptoms of hydrocephalus. Each patient received radiotherapy, which was preceded by chemotherapy in 77.1%, and surgery in 31.4% of the cases. The majority of the patients received radiotherapy to the ventricular system (51.4%), craniospinal irradiation (34.3%), or whole-brain radiotherapy (8.6%) followed by a focal boost in 88%. The remaining patient was treated with focal radiotherapy only. The 5- and 10-year overall survival rate was found to be 97% and 87% respectively, including two patients who died despite disease control (pulmonary and ventricular embolism). The 5-year progression-free survival was 83%. CONCLUSIONS Despite variability in treatment methods, there is a relatively high cure and survival rate in patients with intracranial germinoma. However, the rare occurrence of the disease seems to negatively impact the diagnostic process. The tumor is often diagnosed at an advanced stage, presenting significant, often irreversible symptoms.
Factors and Challenges in Understanding SARS-CoV-2 RNA Levels, Symptoms, and Transmissibility
Authors: Zheng Quan Toh, Lien Anh Ha Do, Paul V. Licciardi
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal